Fundamental Value Approach to Income

December 2023



Value approach to Income through Dividend Equity & Credit, hedged with Gold exposure


1. Steady Income (5% p.a.†) from Dividend Equities & Credit

[†]The dividend amount or dividend rate is not guaranteed.



*The Sub-Fund does not invest directly in commodities; exposure to commodities is obtained through Gold-Related Securities in compliance with applicable laws and regulations.


3. Income from Bonds: Quality, value credits



2. Income from Equities: Quality, dividend-paying equities Trading at a discount to intrinsic value



4. Protection Against Inflation: Gold Exposure



AMUNDI

- Largest European asset manager in the Global Top 10*
- > € 1.9 trillion or U\$2.0 trillion total AuM²
- € 829 billion in ESG AuM³

FIRST EAGLE

- Founded in 1864 with over 158 years of investment management
- Value Investing with a long-term approach to wealth preservation
- Offices in New York, Chicago, Dallas, Baltimore, Los Angeles, Boston, London & Munich
- Over US\$ 131 billion in AuM as of 30 June 2023

Sources: Amundi, First Eagle & Bloomberg. Unless otherwise stated, all data as at 31 December 2023. Past performance is not indicative of future returns. Please consult the Singapore Prospectus and Product Highlights Sheet which are available and may be obtained from Amundi Singapore Limited for a comprehensive explanation on all fees and risks related to the Fund. *No.1 European asset manager based on global assets under management (AUM) and the main headquarters being based in Europe — Source IPE "Top 500 asset managers" published in June 2023 and based on AUM as at December 2022. 1 -This is the target discount between the intrinsic value and share price. Any forecast, projection or target is indicative only and is not guaranteed in any way. Amundi accepts no liability for any deviation to the forecast, projection or target. 2 - As of 30 September 2023, including Lyxor. 3 - As of 30 June 2023.

Track Record

		1M	ЗМ	6M	1Y	3Y	5Y	Since Inception
Bid to Bid Returns	AS-MD	+2.55%	+2.45%	-0.42%	+6.37%	+3.07%	+4.70%	+3.72%
	AHS-MD	+3.59%	+5.43%	+1.11%	+6.23%	+2.33%	+4.56%	+2.96%
Offer to Bid* Returns (net 5% sales charge)	AS-MD	-2.33%	-2.43%	-5.16%	+1.30%	+1.40%	+3.68%	+3.06%
	AHS-MD	-1.34%	+0.41%	-3.70%	+1.17%	+0.68%	+3.55%	+2.38%


Source: Amundi as of 31 December 2023. First Eagle Amundi Income Builder Fund AS-MD inception date: 29/04/2016; AHS-MD inception date: 23/04/2015. Past performance is not indicative of future performance of the Fund. The Sub-Fund has no official benchmark. Annualised returns for periods exceeding 1 year (365 days basis). Returns are computed on the assumption that all dividends and distributions are reinvested, taking into account all charges which would have been payable upon such reinvestment. *Offer to Bid returns include an assumed sales charge of 5%, which may or may not be charged to investors.

Top 5 Equity & Credit Holdings

Top o Equity & Ground Holanigo					
Stock	Fund				
Unilever	3.2%				
Nestle	2.6%				
Jardine Matheson	2.6%				
Exxon Mobil	2.2%				
Colgate-Palmolive	2.1%				
Bond issuer	Fund				
SEG Holding 5.625% 15-Oct-2028	0.7%				
IHO Verwaltungs GmbH 4.75% 15-Sep-2026	0.7%				
Acco Brands Corporation 4.25% 15-Mar-2029	0.7%				
Canpack US LLC 3.875% 15-Nov-2029	0.6%				
Citgo Petroleum 7.0% 15-Jun-2025	0.6%				

Portfolio allocations may vary over time. References to specific securities are presented to illustrate the application of our investment philosophy only and are not to be considered recommendations. It should not be assumed that investments in the securities identified were or will always be profitable.

Portfolio Breakdown - By Asset



Portfolio allocations may vary over time. The Fund does not invest directly in commodities; exposure to commodities is obtained through Gold-Related Securities in compliance with applicable laws and regulations.

Dividend History¹ (The dividend amount or dividend rate is not guaranteed.)

Davied	AS-MD	AHS-MD Annualized Yield		
Period	Annualized Yield			
Dec 2023	5.11%	5.10%		
Nov 2023	5.12%	5.12%		
Oct 2023	5.15%	5.13%		
Sep 2023	5.12%	5.12%		
Aug 2023	5.09%	5.09%		
Jul 2023	5.11%	5.12%		
Jun 2023	5.14%	5.15%		
May 2023	5.10%	5.08%		
Apr 2023	5.13%	5.14%		
Mar 2023	5.15%	5.14%		
Feb 2023	5.10%	5.10%		
Jan 2023	5.14%	5.13%		

1-Portfolio yield figures are subject to changes as a result of market movements and can be lower or higher in the future. Sources: Amundi, First Eagle & Morningstar. Unless otherwise stated, all data as at 31 December 2023. Please consult the Singapore Prospectus and Product Highlights Sheet which are available and may be obtained from Amundi Singapore Limited for a comprehensive explanation on all fees and risks related to the Fund.

	AU2-MD	AHS-MD	AS	AS-MD	A2U-MD	A2S	A2S-MD	A2HS-MD
Share Class Currency	USD	SGD	SGD	SGD	USD	SGD	SGD	SGD
ISIN codes	LU1150488218	LU1150488135	LU1332727632	LU1332727715	LU1412470004	LU1412470699	LU1412471077	LU1412470343
Share class Inception date	20/04/2015	23/04/2015	01/06/2016	29/04/2016	30/06/2016	28/10/2016	16/09/2016	27/09/2016
Sales Charge	Max 5.0%							
Management Fees	Max 1.6% p.a.				Max 1.8% p.a.			
Ongoing Charges	1.8%				2.0%			
Performance Fees & Details	15.0% SOFR + 330 bps p.a. (HWM system)				None			
Dividend Frequency*	Monthly Distribution	Monthly Distribution	Accumulation	Monthly Distribution	Monthly Distribution	Accumulation	Monthly Distribution	Monthly Distribution

Important and Legal Information

Monthly dividends will be distributed on the last Business Day of each month. The dividend may be distributed out of dividend/interest income and/or capital gains and (in the event that dividend/interest income and/or capital gains are insufficient) out of capital attributable to the relevant share class. Investors should also note that the declaration and/or payment of distributions (whether out of dividend/interest income, capital gains, capital or otherwise) may have the effect of lowering the NAV of the relevant share class. Past payout yields and payments do not represent future payout yields and payments. This document contains information about A2U-MD, A2S, A2S-MD, A2HS-MD, AU2-MD, AHS-MD, AS and AS-MD of the First Eagle Amundi Income Builder Fund (the "Fund"), a sub-fund of First Eagle Amundi (formerly known as Amundi International SICAV), an undertaking for collective investment in transferable securities existing under Part I of the Luxembourg law of 17 December 2010, organised as a société d'investissement à capital variable and registered with the Luxembourg Trade and Companies Register under number B55.838 and having its registered office at 5, allee Scheffer, L-2520 Luxembourg. The management company of the Fund is Amundi Luxembourg S.A., 5, allée Scheffer, L-2520 Luxembourg and the Singapore Representative of the Fund is Amundi Singapore Limited (Registration No. 198900774E), 80 Raffles Place, UOB Plaza 1, #23-01, Singapore O48624. (Amundi Luxembourg S.A. and/or its affiliated companies, including without limitation Amundi Singapore Limited, being hereinafter referred to individually or jointly as "Amundi"). Amundi Singapore Limited is regulated by the Monetary Authority of Singapore.

This is a marketing communication. Investors should read the Singapore Prospectus and the Product Highlights Sheet before deciding to invest in the Fund. The share classes of the Fund available for offer to the retail public in Singapore are set out in the Singapore Prospectus and the Product Highlights Sheet, which together with the latest annual and semi-annual reports (if any) may be obtained, free of charge, at the registered office of the Singapore Representative of the Fund or at www.amundi.com.sg or the Fund's authorised distributors. This document is for information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell the Fund in any jurisdiction where such offer, solicitation or invitation would be unlawful.

This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any U.S. Person (as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933 and in the Singapore Prospectus of the Fund). The Fund is not registered in the United States under the Investment Company Act of 1940 and shares of the Fund are not registered in the United States under the Securities Act of 1933. Accordingly, this document is for distribution or to be used solely in jurisdictions where it is permitted and to persons who may receive it without breaching applicable legal or regulatory requirements, or that would require the registration of Amundi or its affiliates in these countries. **Past performance and any forecasts made are not indicative of future performance of the Fund**.

Please note that distribution/dividends (if applicable) are not guaranteed unless otherwise stated in the dividend policy for the relevant share class contained in the Singapore Prospectus. Investors should review the relevant dividends disclosure report (if applicable) found on www.amundi.com.sg.

Important and Legal Information (Continued)

Any opinion or view presented is subject to change without notice. The information on this document is intended for general circulation without taking into account the specific investment objectives, financial situation or particular needs of any particular investor. An investor may wish to seek advice from a financial adviser regarding the suitability of the Fund, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before making a commitment to purchase shares in the Fund. Where applicable and contemplated in the Singapore Prospectus, the Fund may invest in financial derivatives as part of its strategy, and a material portion of the returns may be generated from financial derivative strategies. In such scenarios, the Fund will be subject to risks associated with such investments as further detailed in the Singapore Prospectus. Additional risk factors are described in the Singapore Prospectus. Investments in the Fund are subject to investment risks, including the possible loss of the principal amount invested. Such activities may not be suitable for everyone. Value of the shares in the Fund and the income accruing to the shares, if any, may fall or rise. Any forecast, projection or target is indicative only and is not guaranteed in any way.

Such information is solely indicative and may be subject to modification from time to time. It is the responsibility of investors to read the legal documents in force in particular the current Singapore prospectus of the Fund. Subscriptions in the Fund will only be accepted on the basis of their latest prospectus available in English and/or the Product Highlights Sheet. A summary of information about investors' rights and collective redress mechanisms can be found in English on the regulatory page at https://about.amundi.com/Metanav-Footer/Quick-Links/Legal-documentation. Information on sustainability-related aspects (if applicable) can be found at https://about.amundi.com/Metanav-Footer/Quick-Links/Legal-documentation.

References to specific securities are presented to illustrate the application of our investment philosophy only and are not to be considered recommendation by Amundi.

Pursuant to the new Guidelines on marketing communications under Regulation (EU) 2019/1156 of 20 June 2019 on cross-border distribution of funds issued by the European Securities and Markets Authority (ESMA), performance returns which are less than 12 months will not be reported for European domiciled funds.

The information contained in this document is as at **31 December 2023** except where otherwise stated. The information contained in this document has been obtained from sources believed to be reliable but has not been independently verified, although Amundi and its affiliated companies believe it to be fair and not misleading. Amundi does not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this document. Amundi and its associates, directors, connected parties and/or employees may from time to time have interests and or underwriting commitments in the investments mentioned in this document. Amundi does not guarantee that all risks associated to the transactions mentioned herein have been identified, nor does it provide advice as to whether you should enter into any such transaction. Amundi does not make any representation as to the merits, suitability, expected success, or profitability of any such transaction mentioned herein. **This advertisement or publication has not been reviewed by the Monetary Authority of Singapore**. The information contained shall not be copied, reproduced, modified, translated or distributed without the prior written approval of Amundi.

Date of publication: 7 February 2024 Doc ID: 3030769, master template is valid until 31 December 2023.